Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Spruce Biosciences Inc (Spruce Biosciences) is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company pipeline products including Tralesinidase Alfa (TA-ERT) for the treatment of mucopolysaccharidosis type IIIB (sanfilippo syndrome type B); and SPR202 which treats congenital adrenal hyperplasia (CAH).Spruce Biosciences focuses on reducing the hyperresponsiveness of adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol and improve disease control and glucocorticoid steroid burden. The company offers services such as medical services, healthcare services, clinical trials, among others. Spruce Biosciences is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
611 Gateway Boulevard, Suite 740, South San Francisco, California, 94080
Website
sprucebio.com
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPRB (NASD)
EPS
XYZ
Net Income (2024)
XYZ
26.5%
(2024 vs 2023)
Market Cap*
$121.9M
Net Profit Margin (2023)
XYZ
-127.4%
(2024 vs 2023)
* As of and is in US$
Spruce Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Tralesinidase Alfa (TA-ERT): Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B) SPR202: Congenital Adrenal Hyperplasia (CAH) |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Purchase | In April, the company acquired tralesinidase alfa (TA-ERT) from BioMarin. |
| 2024 | Contracts/Agreements | In October, the company signed an agreement to purchase certain assets—including intellectual property, inventory, and contracts—linked to particular pharmaceutical products from AVX (ABC) LLC for US$5 million. |
| 2023 | Contracts/Agreements | In January, the company entered into a licensing agreement with Kaken Pharmaceutical Co. Ltd for the development and commercialization of Spruce’s product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia in Japan. |
Competitor Comparison
| Key Parameters | Spruce Biosciences Inc | Crinetics Pharmaceuticals Inc | Lipocine Inc | Tempest Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | San Diego | Salt Lake | Brisbane |
| State/Province | California | California | Utah | California |
| No. of Employees | 14 | 594 | 14 | 4 |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Grey | Chairman | Executive Board | 2017 | 73 |
| Javier Szwarcberg, M.D | Chief Executive Officer; Director | Executive Board | 2022 | 56 |
| Kirk Ways, M.D., Ph.D | Chief Medical Officer - Interim; Director | Executive Board | 2021 | 74 |
| Samir Gharib | Chief Financial Officer; President | Senior Management | 2022 | 43 |
| Corwin Dale Hooks | Chief Commercial Officer | Senior Management | 2026 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer